Toward a population-based assessment of death due to pulmonary embolism in New Mexico

Sperry, Kris; Key, Charles R.; Anderson, Robert E.

doi:10.1016/0046-8177(90)90124-n

Cited by 40 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…medical) patients. Studies in the USA and Scandinavia confirmed that of the autopsy-proven fatal PE that occurred, 69-85% were in medical patients [12][13][14].…”

Section: Incidence Of Fatal Pulmonary Embolism In Medical Patientsmentioning

confidence: 80%

Pulmonary Embolism in Medical Patients: Improved Diagnosis and the Role of Low-Molecular-Weight Heparin in Prevention and Treatment

Merli

2004

J Thromb Thrombolysis

View full text Add to dashboard Cite

Pulmonary embolism is the major complication of deep-vein thrombosis (DVT) and has been shown in autopsy studies to account for 5-10% of hospital deaths. Approximately 75% of fatal pulmonary emboli (PE) occur in medical patients, a clinically heterogeneous group of patients. Ten percent of deaths due to PE occur within the first hour of the acute thrombotic event. Unfortunately, only 25% of all PE are diagnosed and receive appropriate treatment. The major focus for preventing this complication in medically ill hospitalized patients is to provide venous thromboembolism (VTE) prophylaxis. Unfractionated heparin (UFH) was the mainstay for preventing VTE in hospitalized medical patients. However, over the past few years, low-molecular-weight heparins (LMWHs) have been shown to be at least as effective and safer in preventing VTE in this population. Although highly effective in preventing VTE, there remains a small incidence of thrombotic events. Therefore, clinicians must be attentive to the symptoms and signs that would indicate a PE. If a PE is confirmed, then appropriate treatment based on the clinical status of the patient with either LMWH or body-weight dose-adjusted UFH is indicated.

show abstract

“…medical) patients. Studies in the USA and Scandinavia confirmed that of the autopsy-proven fatal PE that occurred, 69-85% were in medical patients [12][13][14].…”

Section: Incidence Of Fatal Pulmonary Embolism In Medical Patientsmentioning

confidence: 80%

Pulmonary Embolism in Medical Patients: Improved Diagnosis and the Role of Low-Molecular-Weight Heparin in Prevention and Treatment

Merli

2004

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

“…Low-molecular-weight heparins (LMWHs) are used in the treatment of venous thromboembolism, which frequently occurs among patients and is an avoidable cause of death [31][32][33][34][35][36][37][38]. For immobile, polysemic, and dehydrated COPD patients, prophylaxis is recommended.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, in this guideline, the use of LMWH for infectious asthma exacerbations was considered appropriate [10,33]. Studies have shown that for each attempt to avoid deep vein thromboembolism, the use of LMWH resulted in $391 savings based on a pharmacoeconomic model, although the use of this drug was a large portion of the total DPP budget of the hospital [34,36].…”

Section: Discussionmentioning

confidence: 99%

Are treatment guides and rational drug use policies adequately exploited in combating respiratory system diseases?

Doğan¹,

Mutlu²,

Yılmaz³

et al. 2016

Journal of Infection and Public Health

View full text Add to dashboard Cite

The aim of the present study was to increase awareness regarding the rational use of medicines. The data were obtained via the Material Resources Management System Module of the Ministry of Health. For the appropriateness of treatments, the Global Initiative for Asthma, the Global Initiative for Chronic Obstructive Lung Disease, and the guidelines for the rational use of medicines were used. We also investigated whether any de-escalation method or physical exercise was performed. Statistical analyses were performed using descriptive statistics to determine the mean, standard deviation, and frequency. The results showed that healthcare providers ignored potential drug reactions or adverse interactions, and reflecting the lack of adherence to the current treatment guides, 35.8% irrational use of medicines was recorded. Thus, de-escalation methods should be used to decrease costs or narrow the antibiotic spectrum, antibiotic selection should consider the resistance patterns, culturing methods should be analyzed, and monotherapy should be preferred over combination treatments.

show abstract

“…14 The risk of recurrent VTE continues for up to 90 days after hospitalization. 15,16 Approximately 60% of VTE events 17 and 75% of autopsyconfirmed fatal PE [18][19][20][21] occur in nonsurgical patients. More importantly, PE and proximal DVT are occurring more frequently in medical patients than in surgical patients.…”

Section: Introductionmentioning

confidence: 99%

ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients

Mahan

Spyropoulos

2012

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Toward a population-based assessment of death due to pulmonary embolism in New Mexico

Cited by 40 publications

References 9 publications

Pulmonary Embolism in Medical Patients: Improved Diagnosis and the Role of Low-Molecular-Weight Heparin in Prevention and Treatment

Pulmonary Embolism in Medical Patients: Improved Diagnosis and the Role of Low-Molecular-Weight Heparin in Prevention and Treatment

Are treatment guides and rational drug use policies adequately exploited in combating respiratory system diseases?

ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients

Contact Info

Product

Resources

About